Zim Laboratories

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE518E01015
  • NSEID: ZIMLAB
  • BSEID: 541400
INR
147.95
-0.2 (-0.13%)
BSENSE

Nov 20

BSE+NSE Vol: 1.43 lacs

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy
Comparison
Company
Score
Quality
Valuation
Financial
Technical
Valiant Laborato
Kilitch Drugs
Anuh Pharma
Haleos Labs Limi
Shree Ganesh Rem
Zim Laboratories
Wanbury
Themis Medicare
Aptus Pharma
Transchem
Influx Health.
Why is Zim Laboratories Ltd ?
1
Weak Long Term Fundamental Strength with a -18.16% CAGR growth in Operating Profits over the last 5 years
  • The company has been able to generate a Return on Equity (avg) of 5.93% signifying low profitability per unit of shareholders funds
2
The company has declared Negative results for the last 10 consecutive quarters
  • PBT LESS OI(Q) At Rs -5.04 cr has Fallen at -111.76%
  • PAT(Q) At Rs -2.05 cr has Fallen at -388.1%
  • ROCE(HY) Lowest at 3.86%
stock-recommendationReal-Time Research Report
Verdict Report
How much should you sell?
  1. All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Zim Laboratories for you?

High Risk, High Return

Absolute
Risk Adjusted
Volatility
Zim Laboratories
102.64%
1.97
52.20%
Sensex
-2.0%
-0.13
14.98%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors
Factor
Value
Sales Growth (5y)
7.33%
EBIT Growth (5y)
-18.16%
EBIT to Interest (avg)
2.88
Debt to EBITDA (avg)
2.56
Net Debt to Equity (avg)
0.43
Sales to Capital Employed (avg)
1.18
Tax Ratio
22.39%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
1.36%
ROCE (avg)
7.79%
ROE (avg)
5.93%
stock-recommendationValuation
Valuation Scorecard stock-summary
stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary
Factor
Value
P/E Ratio
384
Industry P/E
40
Price to Book Value
2.72
EV to EBIT
157.26
EV to EBITDA
33.00
EV to Capital Employed
2.20
EV to Sales
2.22
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
1.40%
ROE (Latest)
0.71%
Loading Valuation Snapshot...
stock-recommendationTechnicals
Technical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
Bearish
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bullish
No Trend
OBV
Bullish
Bullish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend
Financial Trend Scorecard stock-summary
stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

5What is working for the Company
OPERATING CF(Y)

Highest at Rs 49.53 Cr

NET SALES(Latest six months)

At Rs 199.63 cr has Grown at 24.40%

-12What is not working for the Company
PBT LESS OI(Q)

At Rs -5.04 cr has Fallen at -111.76%

PAT(Q)

At Rs -2.05 cr has Fallen at -388.1%

ROCE(HY)

Lowest at 3.86%

DEBT-EQUITY RATIO(HY)

Highest at 0.51 times

Loading Valuation Snapshot...
Here's what is working for Zim Laboratories
Operating Cash Flow - Annually
Highest at Rs 49.53 Cr and Grown
each year in the last three years
MOJO Watch
The company has generated higher cash revenues from business operations

Operating Cash Flows (Rs Cr)

Net Sales - Latest six months
At Rs 199.63 cr has Grown at 24.40%
Year on Year (YoY)
MOJO Watch
Near term sales trend is positive

Net Sales (Rs Cr)

Here's what is not working for Zim Laboratories
Profit Before Tax less Other Income (PBT) - Quarterly
At Rs -5.04 cr has Fallen at -111.76%
Year on Year (YoY)
MOJO Watch
Near term PBT trend is very negative

PBT less Other Income (Rs Cr)

Profit After Tax (PAT) - Quarterly
At Rs -2.05 cr has Fallen at -388.1%
Year on Year (YoY)
MOJO Watch
Near term PAT trend is very negative

PAT (Rs Cr)

Debt-Equity Ratio - Half Yearly
Highest at 0.51 times
in the last five half yearly periods
MOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio